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Introduction 
 
 Pregnancy is a period of a woman’s life that can be a joyous occasion. There is 
excitement with beginning or expanding a family, selecting names, preparing a nursery, 
and bonding with other women who have experienced pregnancy and childbirth. During 
this time women often take actions to be as healthy as possible. They do their best to eat 
the right foods, attend regular medical appointments, and take prenatal vitamins. Many 
women will change their behaviors, such as quitting smoking and eliminating alcohol; 
however, there are women, despite their desire to have a healthy baby, who continue to 
use alcohol and illicit drugs during pregnancy. 
 
 In 2009, results published from the 2002-2003 National Survey on Drug Use and 
Health found that 25.8% of pregnant women had used a substance (illicit drugs, alcohol, 
or cigarettes) during pregnancy and 4.7% had used illicit drugs (1).  In 2010, the 
Substance Abuse and Mental Health Services Administration published findings from the 
2008-2009 National Survey on Drug Use and Health and found that an average of 4.5% 
of pregnant women had used illicit drugs in the past month (2).  
National data from 2008, suggests that overall 7% of women received no or late 
prenatal care (3), which suggests the majority of women in the United States receive at 
least some level of prenatal care. Given that women are likely to receive prenatal care and 
they are motivated to improve their health during pregnancy, prenatal medical 
appointments provide an opportunity to screen women for drug and alcohol use.  
 Identifying pregnant substance using women is challenging. Toxicology tests may 
produce false negatives due to the “window of detection,” which is the period of time that 
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a substance can be detected. This window is effected by numerous conditions, including 
type of drug, route, type of biological specimen, sensitivity and specificity of the test 
being administered, and metabolism rates, which vary between women and are 
influenced by such things as body type and food intake near time of using substances (4). 
Self-report may provide important information about substance use; however, accurate 
self-report to a medical provider can be impeded due to the stigma associated with drug 
use during pregnancy and a variety of fears, including involvement with child protective 
services (5), judgment by providers (5), reporting use to other people (6), and 
repercussions from mandatory reporting laws (6).  
The combination of screening with self-report followed by assessment has been 
found to be as effective in identifying pregnant women who use drugs or alcohol 
compared to only urinalysis. In one study with pregnant women, screening with the 
Substance Abuse Subtle Screening Inventory (SASSI) was as effective in detecting 
alcohol and cocaine use when compared to a self-report survey and urinalysis (7). A total 
of 1,251 women who registered for prenatal care at the Toledo Hospital (Ohio) were 
enrolled in this study. The results of this study were published in 1999 and the article did 
not indicate the timeframe that data collection occurred. An interview nurse reviewed 
each patient’s substance use history and administered the SASSI and urinalysis. Fifty-
four percent of these women were identified as using alcohol or drugs through self-report, 
a positive SASSI screening, or a positive urinalysis.  The authors of this study state that 
no one method was able to identify all women who were using, but that the combination 
of multiple methods proved to be most effective.  In 2005, Chasnoff and colleagues 
reported on the use of the 4P’s Plus© screening tool compared to urinalysis in identifying 
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pregnant women using alcohol or drugs (8). In this study 4,865 women were screened 
using the 4Ps Plus©. Of these, 1435 pregnant women had urinalysis ordered. In the 
overall study population 1.2% of the women were identified using urinalysis and 37% 
were identified using the 4P’s Plus©. This finding suggests that verbal screening and 
assessment may be more likely to identify pregnant women who are using alcohol or 
drugs as compared to urinalysis.  
Universal verbal screening of pregnant women for illicit drugs is recommended 
by a variety of organizations, including the American Congress of Obstetricians and 
Gynecologists (ACOG) (6) and the American Society of Addiction Medicine (ASAM) 
(9). In addition to verbal screening, brief intervention and referral to care is also 
recommended (10). Screening, using non-biochemical tests, can be effective in 
identifying a woman who is using substances only if she is willing to disclose her use. If 
a woman is identified as using alcohol or drugs during her pregnancy, she is likely to 
have improved maternal and infant outcomes if she receives appropriate treatment (11).  
The primary objective of this paper is to report findings of survey responses that 
explore the disclosure behaviors of women who have used illicit drugs during pregnancy, 
experiences with brief interventions, and referral to care during prenatal appointments. A 
secondary goal is to explore the willingness of women to answer questions about drug 
use during pregnancy in a self-administered Internet-based survey format.  
Background 
 The purpose of verbal screening for alcohol and other drug use in a medical 
setting is to identify individuals who are actively using alcohol or drugs. Once a person is 
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identified, a conversation can be had to determine the extent of the use and if further 
assessment and referral to treatment is warranted.  
 Verbal screening for alcohol and drug use can be conducted in healthcare settings. 
Standardized alcohol and drug use screening tools have been developed and are utilized 
in primary care, obstetric, and specialty healthcare settings. Some commonly used 
screening tools include Cut Down, Annoyed, Guilty, Eye-Opener (CAGE) (10); Drug 
Abuse Screening Test (DAST) (10); and Alcohol, Smoking, Substance Involvement 
Screening Test (ASSIST) (10). Screening does not provide diagnosis but may indicate if 
a patient is in need of follow-up, which could include brief intervention, brief treatment, 
or referral for treatment with a specialist. Screening for alcohol and other drug use has 
been found to be feasible in a variety of healthcare settings and among diverse 
populations (12). 
 Screening tools have been developed and validated for use with women, in 
general, and with pregnant women specifically (6, 13). The T-ACE and TWEAK 
screening tools were designed to assess alcohol-specific use among pregnant women. The 
T-ACE screening tool, which is based on CAGE, comprises the following questions:  
1. Tolerance: How any drinks does it take to make you feel high? 
2. Have people annoyed you by criticizing your drinking? 
3. Have you ever felt you out to cut down on your drinking? 
4. Eye-opener: Have you ever had a drink first thing in the morning to steady your 
nerves or get rid of a hangover? 
 
The 4 Ps © screening tool (8) asks about both alcohol and drug use during pregnancy and 
comprises the following questions: 
 
1. Have you ever used drugs or alcohol during this Pregnancy? 
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2. Have you had a problem with drugs or alcohol in the Past? 
3. Does your Partner have a problem with drugs or alcohol? 
4. Do you consider one of your Parents to be an addict or alcoholic? 
 
 
In 1999 (14) and 2007 (15) surveys were distributed to Fellows of the American 
College of Obstetricians and Gynecologists regarding screening and opinions about 
alcohol use during pregnancy. Although most obstetricians and gynecologists, about 92% 
in both studies, asked about alcohol use at the initial visit, few used a validated screening 
tool. Both studies indicated the providers needed additional information regarding 
referral options for patients who need treatment, and providers needed additional 
education regarding screening techniques and the effects of alcohol use during 
pregnancy. In 1999, 30% of the surveyed providers felt prepared to assess alcohol use, 
and in 2007 this increased to 72%. 
The article titled “Alcohol Consumption During Pregnancy” discusses alcohol use 
and provider screening practices from the patient’s perspective (16). This study was 
conducted among 12,611 women from Maryland who had a live birth between the years 
2001 to 2008. The response rate for the study was 72%. The women were sent the survey 
by mail two to nine months postpartum. Nineteen percent reported they were not asked 
about alcohol use during prenatal care. The study found that 8% of these women drank 
alcohol in the last three months of pregnancy. This finding is similar to national data. The 
Pregnancy Risk Assessment Monitoring System (PRAMS) is a national surveillance 
project that “collects state-specific, population-based data on maternal attitudes and 
experiences before, during, and shortly after pregnancy (17).” PRAMS data, collected in 
1996-1999 from 50,461 women, indicated 7.9% of women drank during the last three 
months of pregnancy (18). The National Birth Defects Prevention Study data, collected in 
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1997-2002 from 4,088 women, reported 5.5% of women drank alcohol during the last 
three months of pregnancy (19).  
The state of Connecticut received funds from the Centers for Disease Control and 
Prevention (CDC) to begin PRAMS data collection starting in 2013 (20) and previously 
collected data similar to PRAMS using the state-sponsored Pregnancy Risk Assessment 
Tracking System (PRATS). In 2006, the report “Results of the Connecticut PRATS 
Survey Round 2” was released. Eligible participants in this survey were a random sample 
of 4,480 mothers who delivered between November 2002 to June 2003 (21). Forty-four 
percent of the eligible participants responded (n=1982). In this sample, 75.7% of the 
respondents had a discussion with a health care worker during prenatal appointments 
about how alcohol use could affect the baby and 64.2% stated they discussed how use of 
illicit drugs could affect the baby.  
Other studies have reported on the prevalence of counseling and health education 
during prenatal care from the patient’s perspective. Using PRAMS data, Peterson and 
colleagues reported 73% of the participants received preventative counseling about illegal 
drug use and 81% received preventative counseling about alcohol use during prenatal 
appointments  (22).  
The Screening, Brief Intervention, and Referral to Treatment (SBIRT) model is an 
evidence-based practice (9) that can be used to identify persons engaging in substance 
use (screening) and followed with appropriate responses (brief intervention and/or 
referral to treatment). SBIRT has been shown to be effective in addressing at risk alcohol 
use (9). The data assessing SBIRT effectiveness in addressing illicit drug use is 
promising (9). In a 2008 study (10), pregnant women who received screening, 
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assessment, and treatment had better birth outcomes than the group who received only a 
screening. In December 2008 American College of Obstetricians and Gynecologists 
released a Committee Opinion titled “At-Risk Drinking and Illicit Drug Use: Ethical 
Issues in Obstetric and Gynecologic Practice” (6). This publication states: 
 
Obstetricians-gynecologists have an ethical obligation to learn and use a protocol 
of universal screening questions, brief intervention, and referral to treatment in 
order to provide patients with medical care that is state-of-the-art, comprehensive 
and effective. (p.1) 
  
 SBIRT activities are validated through research findings, endorsed by 
professional organizations, and financially supported through national resources. 
SAMHSA is supporting SBIRT implementation through grants, trainings, and national 
resources. In a July 2012 announcement, three states received 22 million dollars of 
funding from SAMHSA to expand SBIRT activities (23). In 2008, SAMHSA provided 
3.75 million dollars to implement SBIRT training programs for medical residents (24). 
The Institute for Research, Education & Training in Addictions, received funding from 
SAMHSA to create a National SBIRT Addiction Technology Transfer Center (N-SBIRT 
ATTC) (25). The N-SBIRT ATTC provides technical assistance, disseminates 
information, and training on SBIRT.      
 
 
Clinical Experience 
 The author has 15 years of experience working with people who have used illicit 
substances and 6 years of experience working primarily with pregnant and parenting 
women with histories of substance use disorder. Conversations with patients about 
disclosure of substance use to prenatal providers influenced the development of the 
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survey questions. Several patients stated their prenatal providers did ask about alcohol 
use but did not ask them about illicit drug use. Patients stated they were willing to 
disclose their drug use but wanted the provider to bring up the topic since they were 
unsure how to broach the subject. This clinical work and discussions with patients 
suggest that women are willing to discuss their drug use during pregnancy and that they 
have a profound desire to address their substance use and mitigate the potential risks to 
the newborn.  
Development of the Pregnancy and Drug Use Questions (PDUQ) 
The SBIRT model and the 
author’s clinical 
experience were the main 
influences on the 
development of the core 
concepts of the Pregnancy 
and Drug Use Questions 
(PDUQ) used for this     
              paper. Table 1 presents 
the three activities associated with the SBIRT model and the corresponding questions in 
the PDUQ.  Development of a question to ask about experience with screening was 
straightforward. However, development of questions regarding experience with 
assessment and referral to treatment activities required additional consideration, because 
specific types of assessment and referral activities may differ among providers.  
Table 1 
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 Assessment can include a variety of activities, such as an in-depth conversation 
about extent of drug use, collecting information about lifetime history of drug use, 
discussing readiness and willingness for treatment, and exploring types of treatment 
available. The author was challenged to develop a question that used terms the participant 
could understand and would identify whether a medical provider discussed the topic of 
substance use any further than during screening. Based on clinical experience and 
interactions with medical professionals, if a woman discloses drug use during pregnancy, 
discussion regarding treatment, including a hospital-based detoxification, is common. 
The author decided that asking the participants if their provider talked to them about 
treatment options would be an indicator that assessment occurred.   
 Referral to treatment can include a variety of activities, such as providing a 
patient with a number to call for treatment or the provider may actively facilitate 
treatment admission, such as calling a facility and arranging an intake. The author 
concluded the phrase “help you get into treatment” would be adequate to assess provider 
referral activities.  
 The PDUQ asked only about illicit drug use and did not ask about alcohol use. 
The PRAMS Standard Questions asks about maternal tobacco and alcohol use, but not on 
illicit drug use (26).  The author was specifically interested in illicit drug use and   
The author did not ask about alcohol because she wanted the participants to focus on 
illicit drug use and not include use of alcohol in the responses.  
 The author is a research assistant for the Structures Health and Risk among Re-
entrants, Probations, and Partners (SHARRPP) study at the Yale School of Public Health. 
The SHARRPP self-administered Internet-based survey instrument contains questions 
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about participants experience with housing, education, involvement with the criminal 
justice system, drug use, sexual partners, HIV status and testing, trauma, and physical 
health. The survey takes participants approximately two hours to complete. The author 
and principle investigator, Dr. Kim Blankenship, discussed adding the PDUQ to the 
SHARRPP survey. Dr. Blankenship supported adding the PDUQ to the index participant 
follow up one survey and the sex partner baseline survey. 
Study Description and Methodology 
 SHARRPP is a research project funded by the National Institutes of Health (NIH) 
and the National Institute on Drug Abuse (NIDA). The principle investigator, Dr. 
Blankenship is of American University, with research being conducted at the Yale School 
of Public Health in New Haven, Connecticut. SHARRPP is a three-year longitudinal 
study with all participants completing quantitative self-administered Internet-based 
surveys conducted every six months, with a subset completing qualitative interviews. 
SHARRPP obtained IRB approval through Yale’s Human Research Protection Program. 
 Three hundred index participants (IP) were recruited beginning in July 2011 from 
the greater New Haven, Connecticut, area. Inclusion criteria were (a) released from jail or 
placed on probation in the previous 12 months, (b) controlling charge for the most recent 
offence was a nonviolent drug-related crime, and (c) over 18 years of age. Release from 
jail, date of probation initiation, and controlling offence were verified via a liaison at the 
New Haven Probation and Parole Office and Connecticut’s Offender Inmate Search 
Website (http://www.ctinmateinfo.state.ct.us/). In addition to recruitment of IP, 
SHARRPP conducted exploratory research to assess the willingness of IP to refer their 
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current sex partners to SHARRPP. At the follow-up one survey (IP1) index participants 
were offered recruitment coupons that they could give to any person they had unpaid sex 
with in the past six months. Inclusion criteria for sex partners (SP) were to have a valid 
recruitment coupon and be over the age of 18. All SP will complete a similar survey and 
qualitative interview, every six months, for the remainder of the three-year research 
period.  
 The PDUQ were developed by the author with review and recommendations from 
UNC advisor Dr. Sherri Green, Dr. Kim Blankenship, and SHARRPP Project Manager 
Alana Rosenberg. The PDUQ were added to the IP1 survey and the SP baseline survey 
(SPBL). Both surveys were programmed and administered using Qualtrics. Participants 
presented at the SHARRPP office and completed the surveys on a computer. Data 
collection for IP1 occurred from 3/2/12 to 8/18/12 and data collection for SPBL occurred 
from 6/19/12 to 12/3/12. The analysis of the PDUQ was conducted using Qualtrics, 
Microsoft Access and Excel. Statistical analysis was conducted, as appropriate, given the 
small sample size. The UNC Office of Human Research Ethics deemed the secondary 
data analysis conducted for this masters theses exempt from further IRB review.  
Demographics 
 Participants who were eligible for responding to the PDUQ were those who 
presented to take the IP1 or SPBL survey and identified as female. A total of 73 
participants were eligible the PDUQ series and 16 of those received the full PDUQ series. 
Of the 73 participants eligible for the PDUQ series: 49% were African-American or 
Black, 34% Caucasian, 12% Hispanic, and 3% other. The mean household monthly 
income was $722.31, with a mean of 2.75 persons per residence. Refer to Table 2 for age 
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and race for the eligible 
participants and of participants 
who answered the full PDUQ 
series.  
Results 
 A total of 73 participants 
received the question, “Was  
           there a time when you were using drugs and found out that you were 
pregnant?” Of the 73 participants, 16 answered yes, 54 answered no, and 3 declined to 
answer. The average age when participants most recently used drugs during a pregnancy 
was 25, with an age range from 14 to 36. Of the 16 participants who answered the entire 
PDUQ series, 14 had been incarcerated at least once.  
Screening and Prenatal Care 
         Of the 16 participants, 11 (68.8%) indicated they  
 received prenatal care during the most recent pregnancy 
when they were using drugs. Of those 11 participants, 8 
(72.7%) indicated they were asked about drug use 
during their prenatal care appointments.  
 
Drug Use 
     The most common drugs used during pregnancy 
were crack, marijuana, and heroin. In this study, 11 participants (68.7%) indicated crack 
use, 8 (50%) indicated marijuana use, and 5 (31.3%) indicated heroin use. The other 
Figure 1 
Table 2 
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illicit drugs reported were prescription opiates (3 participants) and cocaine (1 participant).  
Please see Figure 2 for a list of all drugs that were asked about in the PDUQ. Nine of the 
participants indicated polysubstance use and 7 indicated monosubstance use. Of the 16 
participants, 3 (18.8%) reported injecting drugs around the time they became pregnant. 
Drug Treatment 
Participants were asked 
about drug treatment at 
the time they learned they 
were pregnant and their 
subsequent treatment 
engagement. Of the 16 
participants, 3 were in 
drug treatment at the time 
they learned they were  
pregnant. Of the remaining 13 participants, 4 entered treatment and 9 did not. Of the 4 
participants that started treatment after they were aware of the pregnancy, all entered 
within the first month of awareness: 2 entered within one to two weeks, and 2 entered 
within two to four weeks. As for the reason they entered treatment, all 4 participants 
indicated: “I wanted to stop using drugs for the health of the baby.” In this multiple 
choice question, 2 participants also answered: “I was able to get into treatment more 
easily or quickly because I was pregnant”; and 1 participant answered: “I was worried my 
other children would be taken from me if I didn’t enter treatment.”  
Figure 2 
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For the 9 participants who did not enter treatment, the most common reason was 
that they wanted to stop using on their own or simply did not want to enter drug 
treatment. Of those 9 participants, 2 responded they did not enter treatment because they 
did not want people to know they had used drugs during the pregnancy. None of these 
participants indicated that knowledge of where to get treatment, affording treatment, 
finding treatment close to them, or a treatment center waiting list had been a reason to not 
enter treatment.  
Prenatal Care and Disclosure 
A total of 11 participants received prenatal care and 5 did not. Of the 11 
participants who did, 8 (72.2%) were asked about drug use as part of their prenatal care. 
Of the 8 participants who were asked, 7 disclosed they were using drugs. Of the 3 
participants who were not asked, 1 self-disclosed and 2 did not.  
 
 
 
 
Table 3 
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SBIRT 
 Of the 8 participants who were screened, 7 disclosed they were using illicit drugs. 
Of these 7 participants, 6 indicated the provider talked to them about treatment options. 
Of these 6 participants, 4 indicated the provider helped them obtain treatment.  
Willingness to Answer Questions 
 All questions had a response option of “I do not want to answer,” and this 
response option is referred to as “declined.” A participant was deemed willing to answer 
a question if she did not decline to answer a question. There were a total of 216 responses 
to the PDUQ series. Of these 216 responses, there were five questions that participants 
declined to answer. The final question in the PDUQ is “Would you be interested in being 
contacted by one of the research staff to participate in another research study related to 
drug use during pregnancy?” Of the 16 participants, 13 responded yes, 1 responded no, 
and 2 declined to answer this question.   
Discussions, Significant, and Limitations 
In this sample, 21.9% of participants indicated they had used illicit drugs during 
pregnancy, which is a higher percentage than national statistics; however, our sample 
population was made up of women who had histories of drug use or had sex partners who 
engaged in drug use. This finding is consistent with other research (27) that suggests that 
the prevalence of illicit drug use during pregnancy may be greater among women with 
these characteristics as compared to the general population.  
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Having a history of illicit drug use or having a partner who uses illicit drugs are 
risk factors for illicit drug use during pregnancy. Asking women about her history of 
using illicit drugs or alcohol is a common question on screening tools that are used to 
help detect drug use during pregnancy (6, 12, 13), which implies that women with these 
histories may be at more risk of using drugs during pregnancy. The 4 Ps © screen tool 
asks if their partner has a problem with drugs or alcohol (8). One study of 1,226 women, 
those whose stated their partner used marijuana, cocaine, opiates or heavy alcohol use 
(defined as “two or more drinks per day”) were almost five times more likely to use drugs 
or alcohol during their pregnancy, as compared to women who did not report their partner 
engaged in these behaviors (27).   
A review of drug use in pregnancy from 1996 to 1998 (28) found the most 
common illicit drug used during pregnancy was marijuana (75%), followed by cocaine 
(10%). In the PDUQ sample, the most prevalent drug used was crack (68.7%; n=11), 
followed by marijuana (50%; n=8), then heroin (31.3%; n=5).  
 The majority of participants disclosed their use of drugs to their prenatal providers 
and women who were asked about illicit drug use were more likely to disclose their use, 
compared to the participants who were not asked. This finding suggests that women are 
more likely to disclose their illicit drug use if they are asked, compared to self-reporting 
without provider inquiry. This finding also suggests that verbal screening may be helpful 
in identifying pregnant women who are using illicit drugs during pregnancy.  
 To assess for illicit drug use during pregnancy we can ask the woman, test 
maternal biological samples, test infant biological samples, or a combination of the three. 
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Meconium testing of the infant is not invasive and does provide evidence of drug 
exposure in the last two trimesters of pregnancy. However, if we wait for the infant to be 
born, the opportunity for intervention during the pregnancy has been missed. Maternal 
biological drug testing has its limitations as well. There is a risk of false positives due to 
drug metabolizing rates. Additionally, women might engage in behaviors to reduce or 
eliminate the risk of drug detection by abstaining from use for a period of time prior to a 
potential test, using another person’s urine, or diluting a urine sample.  
 Although there is potential for a woman to deny her use of drugs, honest 
disclosure is the most accurate and cost-effective way to determine her use of drugs and 
to assure early and effective intervention for the health of mother and baby. There are 
many reasons why women do not disclose; however, there are conditions that can foster a 
positive patient-provider relationship and establish an environment of trust, which may 
increase the likelihood of her disclosing. A respectful environment includes providers 
who are nonjudgmental, protect patient confidentiality, and are empathetic and caring 
(29). 
 Due to the stigma associated with illicit drug use during pregnancy, women might 
not be willing to disclose details about this life experience; however, this sample was 
very willing to answer such questions. Of the questions in the series, 97% were answered, 
suggesting that the participants were willing to answer questions regarding their drug use 
during past pregnancies. This finding suggests that although drug use during pregnancy is 
a stigmatized behavior, participants were willing to answer self-administered Internet-
based survey questions about their past pregnancies. 
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An exploratory question was included in the PDUQ series to investigate 
participant’s willingness to attend a qualitative interview to discuss drug use during 
pregnancy. This question did not mention any additional compensation for participant’s 
time. A total of 13 participants (81%) indicated they were interested in being contacted 
about participating in a qualitative interview about drug use during pregnancy. Without 
knowing who would be conducting the interview and without explicit knowledge of 
monetary compensation, the majority of participants appear willing to engage in a 
dialogue about this topic.  
Of the 16 participants who reported using during pregnancy, 7 (43.8%) entered or 
were in substance use disorder treatment during the pregnancy. Two common responses 
to why women entered treatment were reasons related to their concern over their current 
pregnancy and other children. This finding continues to support the notion that pregnancy 
increases women’s motivation to engage with substance use disorder treatment (30, 31). 
For the participants who did not enter treatment, the availability, affordability, and access 
to treatment was not indicated, which suggests in this urban population, logistics of 
entering treatment was not a barrier to care. Instead, the reasons women provided were 
internal (not wanting to enter treatment, wanting to stop using on their own) as opposed 
external.   
The Stages of Change model states people move through different stages before 
adopting behavior change (32). These stages are precontemplation, contemplation, 
preparation, action, and maintenance (33). The stages can be used to identify appropriate 
interventions (34), for example: 
 “Action-oriented therapies may be quite effective with individuals who are in the 
 preparation or  action stages. These same programs may be ineffective or 
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 detrimental, however, with individuals in precontemplation or contemplation 
 stages.” (34, p. 1106) 
 
Considering that people in different stages respond more favorably to stage-matched 
interventions, a variety of interventions should be available that are appropriate for 
women in different stages. For example, pregnant women who are using illicit drugs may 
be in the contemplation stage and may be weighing the benefits and consequences of 
change. Pregnant women not yet at the contemplative stage (precontemplative) and not 
willing to consider treatment referral may benefit from education at their prenatal visits. 
Prenatal provides can offer information about the risks of alcohol and other drug use 
during pregnancy as wells as from information about non treatment community supports 
and treatment options available to them should they choose to seek assistance in the 
future. Because women usually attend prenatal appointments several times over the 
course of the pregnancy, a provider can assess which stage she is in, at that time, and 
respond with appropriate interventions. 
The SBIRT model includes the following activities: screening, assessment, and 
referral to care. Of the 7 participants that were screened and disclosed drug use, 6 
discussed treatment options with their provider, and of these 6, 4 indicated their providers 
helped them obtain treatment. In this sample only 4 of the participants experienced all 
three SBIRT activities. This suggests there is an opportunity to improve providers’ 
implementation of the SBIRT model. Providers can access training and technical support 
through the N-SBIRT ATTC (25) and access implementation tool kits, resources, and 
funding through SAMHSA (35). 
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Limitations 
 There are several limitations regarding this study. First, the number of participants 
who answered the PDUQ series is small, which limited the types of analysis that could be 
conducted, and the findings cannot be generalized beyond this sample. This limitation 
could be overcome by gathering data for a longer period of time and seeking out 
opportunities to include the PDUQ into other studies that have enrolled a larger number 
of women representative of broader populations. 
Second, the years that women were using drugs during pregnancy ranged from 
1980 to 2011. Given the twenty-year time span, we are unlikely to assess changes in drug 
trends over this period. In the previous decade, the use of illicit prescription opiates has 
significantly increased, and it is unlikely that this trend would be captured in our data. If 
more participants were recruited, we could then stratify years and assess for possible 
changes in drug trends. Also, the SBIRT model has been researched since the 1980s and 
implementation began in the 1990s (36), therefore some of the providers the participants 
interacted with may not have utilized or even aware of this model. 
Third, the study is prone to recall bias and social desirability bias. Some women 
were required to recall events that occurred 22 years ago. For those participants, recalling 
details about events occurring over 20 years ago may be more challenging, as opposed to 
others who recalled drug use during a pregnancy as recent as 2011. Additionally, 
considering these participants were using drugs during the time we are asking them to 
recall, we cannot assure how the accuracy of the recall has been influenced by drug use.   
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Fourth, this study sample was women in the greater New Haven population who 
had histories of incarceration and/or probation or were sexual partners of people with 
these histories. Because of characteristics of this specific sample, results may not mirror 
findings reported in studies conducted among the general US population.  
Lessons Learned  
  The development of the PDUQ was time sensitive, due to having to coordinate 
inclusion of the questions in the SHARRPP IP FU1 and SPBL surveys. The author 
devoted time to researching which questions should be asked and the content of the 
questions. A more thorough review of the literature and a concrete application of theories 
would have been beneficial to the process of developing the PDUQ. 
 The number of participants who received the PDUQ series was less than 
anticipated. SHARRPP attempted to recruit 100 sex partners; however, at the time of data 
analysis only 49 had presented to take the SPBL. Three-hundred and four IP completed 
the IP baseline survey and, of those, only two-thirds presented for the IP1 survey. If the 
PDUQ had been included in the index participant baseline survey and if sex partner 
recruitment had been more successful, there would have been a greater number of 
participants who received the PDUQ.  
Next Steps 
As mentioned elsewhere in this paper, women appear willing to answer questions 
about past drug use during pregnancies. Given the need for improved surveillance 
regarding illicit drug use during pregnancy, self-administered Internet-based surveys may 
be utilized to collect such information.  
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 Much could be learned from these participants about their personal experience 
and from feedback regarding the PDUQ. At this time, the author has not contacted any of 
the participants to schedule a qualitative interview. Considering that the clinical 
environment and provider-patient relationship influences women’s disclosure behavior, 
qualitative data could be collected on how, exactly, disclosure behavior is influenced.  
 The participating women were willing to answer questions about drug use during 
previous pregnancies; however, we did not assess the willingness to answer questions 
about current drug use and pregnancy. The purpose of screening for drug use during 
pregnancy is to identify women who are currently pregnant and using drugs; therefore, 
assessing the willingness of pregnant women to disclose illicit drug use during current 
pregnancy using a self-administered instrument is a topic that deserves attention.  
 Given the strong support and growing body of evidence for the use of the SBIRT 
model, there is an opportunity to assess implementation efforts. Chart reviews could be 
conducted to identify how many women were screened and how many were exposed to 
all three SBIRT activities. For women who screened positive and did not receive an 
assessment and referral to treatment, we could investigate gaps in the system and identify 
ways to increase assessment and referral activities.  
Observations 
 Women appear to be willing to disclose illicit drug use during pregnancy and they 
are motivated to change health behaviors during pregnancy. Providers have available 
tools to screen, assess, and refer to treatment. Yet, we are lacking adequate national 
surveillance regarding illicit drug use during pregnancy. This begs the question: what are 
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the barriers to addressing this important health issue and including illicit drug use when 
asking questions about alcohol and nicotine?  
 While there are a plethora of potential barriers, one of the most significant is that 
drug use during pregnancy is viewed not only as a health issue but also a legal issue due 
to potential legal ramifications. Furthermore, there is a wider range of policies on illicit 
drug use during pregnancy, across the US. Some states are approaching the issue utilizing 
the criminal justice and legal system while others utilize the healthcare and substance use 
disorder treatment system (37). When the legal system is utilized, of particular concern is 
that there is opportunity for racial discrimination in applying the law. One study that 
enrolled 715 pregnant women in Pinellas County, Florida between January and June 
1989, found that rates of illicit drug use were similar between black and white women; 
however, black women were reported to health authorities 10 times more frequently than 
white women (38). Laws and policies, about mandatory reporting to health authorities or 
law enforcement, have the potential to create a rift in the provider-patient relationship: 
the provider may not ask and the patient may not disclose both concerned about legal 
implications regarding illicit drug use during pregnancy.  Women might also avoid 
prenatal care out of fear of incarceration or losing custody of other children. These 
scenarios result in adverse maternal and fetal outcomes where opportunities to enter 
substance abuse treatment and obtain adequate prenatal care have been missed.  
 There have been significant changes to the substance use disorder field over the 
past several decades. Scientific research has provided us with evidence to support the 
adoption of the chronic disease model of addiction (39) as opposed to addiction being a 
moral flaw. Research has also provided numerous evidence-based practices to assist in 
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the treatment of substance use disorder. Considering that persons with substance use 
disorder have similar treatment adherence and response to treatment as other diseases 
such as asthma, diabetes, and hypertension (40); the author questions the reasoning 
behind state laws and mandatory reporting policies that target pregnant women with 
substance use disorder, which may result in criminal prosecution and incarceration.  
 Two additional potential barriers worth noting are lack of provider education (14, 
15)  and lack of accessible appropriate treatment options for pregnant women who are 
using illicit drugs. Lack of knowledge and training may create a barrier because providers 
may not know how to effectively screen pregnant women and what actions should be 
taken if a verbal screen is positive. If a provider does want to refer to treatment or if a 
woman wants to enter treatment, there is not always appropriate treatment available for 
pregnant women in the local area. This creates a challenge for the provider, as they may 
be reluctant to screen if they know there are no local, or even regional, resources. While 
there is the possibility a woman could relocate for treatment, this may not be practical or 
even feasible given her financial and family situation.    
Conclusion  
 Screening for drug and alcohol use among pregnant women and referral to 
treatment are effective public health activities that can be conducted by healthcare 
providers in a variety of settings. Pregnancy provides a unique opportunity for 
intervention when a woman’s motivation for addressing drug and alcohol use is 
heightened (30, 31). Prenatal care provides an opportunity for healthcare providers to 
verbally screen pregnant women for alcohol and drug use and refer to treatment as 
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appropriate. Given these conditions, public health efforts should continue to identify 
ways to improve adoption and implementation of the SBIRT model by continuing to 
conduct research on this topic and should support the implementation of tools, practices, 
and policies that foster women’s willingness to disclose drug and alcohol use during 
pregnancy. With that said, public health efforts should also continue to assess practices 
and policies that create barriers to both patients and providers to effectively address illicit 
drug use during pregnancy. 
 Many women who have experienced drug use during pregnancy are willing to 
discuss this topic and should continue to be included in current research and in the 
development of tools and policies. These women hold tremendous knowledge and can 
provide significant insights into this public health problem, if we are willing to ask, and, 
more important, to listen. As one of the author’s patients said to her, “I’m happy to tell 
my story if it helps someone else not have to go through what I had to.” Sharing her story 
potentially helped others, at the very least, helped the author both better understand the 
experiences of pregnant women who use drugs and better identify opportunities for 
public health practitioners to improve maternal and child health outcomes. 
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